|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent HHS insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why HHS insider buys are important for investors to follow.
Date | Insider | Price | Amount |
12-1-2023 Insider Buy |
Bradley Louis Radoff Director |
$7.23
CAGR »
|
$144,670.00 20,000 shares |
11-29-2023 Insider Buy |
Bradley Louis Radoff Director |
$6.82
CAGR »
|
$68,197.00 10,000 shares |
11-15-2023 Insider Buy |
Kirk A. Davis Chief Executive Officer |
$7.07
CAGR »
|
$40,551.86 5,739 shares |
8-17-2023 Insider Buy |
John H. Griffin Jr. Director |
$5.62
CAGR »
|
$45,698.14 8,129 shares |
8-17-2023 Insider Buy |
John H. Griffin Jr. Director |
$5.65
CAGR »
|
$4,353.59 771 shares |
8-16-2023 Insider Buy |
Kirk A. Davis Chief Executive Officer |
$5.34
CAGR »
|
$50,954.22 9,542 shares |
5-24-2023 Insider Buy |
Brian Linscott Chief Executive Officer |
$5.57
CAGR »
|
$27,855.00 5,000 shares |
5-11-2023 Insider Buy |
Laurilee Kearnes Chief Financial Officer |
$5.99
CAGR »
|
$9,883.50 1,650 shares |
5-8-2023 Insider Buy |
Brian Linscott Chief Executive Officer |
$5.97
CAGR »
|
$47,759.20 8,000 shares |
3-15-2023 Insider Buy |
Brian Linscott Chief Executive Officer |
$8.94
CAGR »
|
$22,347.25 2,500 shares |
12-12-2022 Insider Buy |
Brian Linscott Chief Executive Officer |
$11.17
CAGR »
|
$27,925.00 2,500 shares |
8-15-2022 Insider Buy |
Brian Linscott Chief Executive Officer |
$14.95
CAGR »
|
$29,907.40 2,000 shares |
2-28-2022 Insider Buy |
Brian Linscott Chief Executive Officer |
$6.55
CAGR »
|
$223,446.50 34,100 shares |
2-28-2022 Insider Buy |
Robert T. Wyman General Counsel |
$6.49
CAGR »
|
$4,867.50 750 shares |
6-11-2020 Insider Buy |
Alfred Victor Tobia Jr. Director |
$2.82
CAGR »
|
$35,416.00 12,554 shares |
6-3-2020 Insider Buy |
John H. Griffin Jr. Director |
$2.66
CAGR »
|
$26,560.00 10,000 shares |
6-1-2020 Insider Buy |
Andrew B. Benett Chief Executive Officer |
$2.33
CAGR »
|
$36,040.00 15,500 shares |
5-21-2020 Insider Buy |
Andrew B. Benett Chief Executive Officer |
$2.45
CAGR »
|
$78,450.00 32,000 shares |
3-17-2020 Insider Buy |
Laurilee Kearnes Chief Financial Officer |
$2.66
CAGR »
|
$2,655.00 1,000 shares |
3-16-2020 Insider Buy |
Evan Behrens
|
$2.70
CAGR »
|
$6,750.00 2,500 shares |
3-17-2020 Insider Buy |
Andrew B. Benett Chief Executive Officer |
$2.70
CAGR »
|
$54,096.35 20,000 shares |
12-15-2016 Insider Buy |
Karen A. Puckett President and CEO |
$1.48
CAGR »
|
$54,908.00 37,100 shares |
6-14-2016 Insider Buy |
Judy C. Odom Director |
$1.72
CAGR »
|
$51,600.00 30,000 shares |
6-10-2016 Insider Buy |
Shirish R. Lal Chief Operating Officer & CTO |
$1.60
CAGR »
|
$22,772.80 14,233 shares |
8-6-2015 Insider Buy |
Judy C. Odom Director |
$4.65
CAGR »
|
$69,750.00 15,000 shares |
8-31-2012 Insider Buy |
Larry Franklin President and CEO |
$7.00
CAGR »
|
$69,974.00 10,000 shares |
8-24-2012 Insider Buy |
Larry Franklin President and CEO |
$7.02
CAGR »
|
$140,362.00 20,000 shares |
8-21-2012 Insider Buy |
Larry Franklin President and CEO |
$7.13
CAGR »
|
$158,987.85 22,300 shares |
8-16-2012 Insider Buy |
Larry Franklin President and CEO |
$6.94
CAGR »
|
$31,917.56 4,600 shares |
8-14-2012 Insider Buy |
David L. Copeland Director |
$6.60
CAGR »
|
$132,077.44 20,000 shares |
Also See: Institutional Holders of HHS
Also See: SEC filings
Below we present the annualized performance delivered by HHS stock since 12-1-2023 (the date of the most recent
insider purchase). The performance of the investment from the time HHS insider buying occurred is the ultimate
test of whether insiders were right about HHS being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/04/2023 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$7.51 |
|
End price/share: |
$6.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-7.06% |
|
Annualized Gain: |
-19.37% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,294.00 |
|
Years: |
0.36 |
|
HHS Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent HHS insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding HHS
|
|